BerandaADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
$0,28
Setelah Jam Perdagangan Normal:(6,61%)-0,018
$0,26
Tutup: 30 Apr, 19.19.31 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$0,26
Rentang hari
$0,26 - $0,28
Rentang tahun
$0,20 - $1,48
Kapitalisasi pasar
73,90Â jt USD
Volume Rata-Rata
2,37Â jt
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 3,22Â jt | 1.294,81% |
Biaya operasional | 28,56Â jt | 199,64% |
Laba bersih | -74,22Â jt | -54,88% |
Margin laba bersih | -2,30Â rb | 88,90% |
Penghasilan per saham | -0,24 | 0,25% |
EBITDA | -61,68Â jt | -55,60% |
Tarif pajak efektif | -2,33% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 151,60Â jt | 3,18% |
Total aset | 245,96Â jt | -12,97% |
Total liabilitas | 234,11Â jt | -3,70% |
Total ekuitas | 11,85 jt | — |
Saham yang beredar | 257,23 jt | — |
Harga terhadap nilai buku | 5,26 | — |
Tingkat pengembalian aset | -57,25% | — |
Tingkat pengembalian modal | -134,10% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -74,22Â jt | -54,88% |
Kas dari operasi | -34,20Â jt | -133,06% |
Kas dari investasi | 8,17Â jt | -88,02% |
Kas dari pembiayaan | 1,00Â rb | -98,65% |
Perubahan kas bersih | -26,22Â jt | -148,60% |
Arus kas bebas | -14,80Â jt | 45,36% |
Tentang
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Didirikan
2008
Situs
Karyawan
506
